TLR2: Toll-like receptor 2
Cooperates with LY96 to mediate the innate immune response to bacterial lipoproteins and other microbial cell wall components.
- Drugs that act on it: 2
- Approved: 0
- In phases 1 to 3: 2
- Sponsors: 2
Who is on it, and how far along
Every drug ChEMBL records acting on TLR2, by the furthest stage it has reached for any use, coloured by modality.
How to read this
Each mark is one drug. Columns run from approved to phase 1; hover or tap a mark for its sponsor, modality and open trials, and click it to open the drug.
- Small molecule 1
- Antibody 1
| Tomaralimab | Phase 2 | Opsona Therapeutics Ltd. | Antibody | AntagonistToll-like receptor 2 antagonist | 0 |
| VB-201 | Phase 2 | Vascular Biogenics Ltd. operating as VBL Therapeutics | Small molecule | InhibitorToll-like receptor 2 inhibitor | 0 |
- Tuberculosis0.49
- Inborn error of immunity0.37
- Neurodegenerative disease0.23
- Attenuated familial adenomatous polyposis0.18
- Colorectal cancer0.18
- Alcohol drinking0.17
- Urolithiasis0.17
- Coronary artery disorder0.16
- Age-related macular degeneration0.15
- Venous thromboembolism0.15
- COVID-19–associated multisystem inflammatory syndrome in adults0.14
- Atopic eczema0.14
Drugs, mechanisms, furthest stage (max phase) and modality (molecule type) are from ChEMBL CHEMBL4163, ChEMBL 37, fetched 2026-11-18 (CC BY-SA 3.0). Sponsors are the US application holder (Drugs@FDA) for approved drugs with a US page, else the industry lead sponsor of the most of the drug's ClinicalTrials.gov trials. Open trials are recruiting or ongoing studies naming the drug as an intervention on ClinicalTrials.gov, checked daily; this page as of 2026-11-21. Gene name, function (UniProt O60603, CC BY 4.0) and disease associations are from Open Targets (CC0). ChEMBL and Open Targets